Browse

Histone Deacetylase Inhibitors for Cancer Therapy

Cited 0 time in Web of Science Cited 67 time in Scopus
Authors
Kim, Tae-You; Bang, Yung-Jue; Robertson, Keith D.
Issue Date
2006-01
Citation
Epigenetics, Vol.1 No.1, pp.14-23
Keywords
histone deacetylasehistone deacetylase inhibitorepigeneticstranscriptionmethylationchromatincancer
Abstract
The epigenome of cancer cells is determined by DNA methylation and an array of post-translational modifications of the core histones. Epigenetic abnormalities are commonly found in human tumors and importantly, they can be reversed by pharmacologic inhibitors. Histone deacetylase inhibitors (HDACIs) represent one of the most promising epigenetic treatments for cancer. HDACIs have emerged as promising targets for cancer therapy because they reactivate the transcription of multiple genes that are silenced in human tumors and they show pleiotropic anti-tumor effects selectively in cancer cells. HDACIs are well-tolerated and several show promising anti-tumor activity. While gene transcription has been considered to be the major target of HDACIs, inhibition of acetylation of non-histone proteins is now emerging as a novel basis for their anti-tumor effects. In this review, we discuss new insights into the molecular mechanism of HDACIs, their current status of clinical development, and possible future uses in cancer therapy.
ISSN
1559-2294
URI
http://hdl.handle.net/10371/173060
DOI
https://doi.org/10.4161/epi.1.1.2644
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse